Thursday, November 19, 2020

Oxford-AstraZeneca Covid vaccine shows robust immune response among older adults

 
A Brazilian doctor voluntarily receives an injection as part of phase 3 trials of a vaccine developed by the University of Oxford and British pharmaceutical company AstraZeneca, in July 2020. Nelson Almeida | AFP | Getty Images

Sam Meredith
NB News

LONDON — The coronavirus vaccine being developed by the University of Oxford and AstraZeneca is safe and triggers a similar immune response among all adults, according to the preliminary findings of a peer-reviewed phase two trial.

The promising early-stage results were published in The Lancet, one of the world’s top medical journals, on Thursday.

The study of 560 healthy adults, including 240 over the age of 70-years-old, found the vaccine to be safe and produced a similar immune response among people aged over 56-years-old and those aged between 18 and 55.  Read more >>